Details of Disease

General Information of Disease (ID: DISSQJN2)

• Disease Name: Epileptic seizures
• Disease Class: 8A61-8A6Z: Epilepsy/seizure
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISSQJN2: Epileptic seizures
• ICD Code:
  ICD-11: ICD-11: 8A61-8A6Z
  ICD-9: ICD-9: 345.9, 780.3
  Expand ICD-9: 345.9,780.3
• Disease Identifiers:
  MONDO ID: MONDO_0005027
  MESH ID: D004827
  UMLS CUI: C0014544
  MedGen ID: 4506
  SNOMED CT ID: 128613002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ganaxolone	DMXJMKF	Approved	Small molecular drug	[1]
Methsuximide	DM6L5VO	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ZK-93423	DMFWMKZ	Phase 3	Small molecular drug	[3]
Carabersat	DMY4OMS	Phase 2	Small molecular drug	[4]
MDL-27192	DM9FXU7	Phase 2	NA	[5]
ADCI	DM59EUY	Phase 1	Small molecular drug	[6]

This Disease is Treated as An Indication in 7 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LOSIGAMONE	DMN9WWL	Discontinued in Phase 3	Small molecular drug	[7]
534U87	DMYOG98	Discontinued in Phase 2	NA	[8]
Dezinamide	DMJT8Q0	Discontinued in Phase 2	Small molecular drug	[9]
LORECLEZOLE	DMCZI62	Discontinued in Phase 2	Small molecular drug	[10]
ADD-17014	DMKPCM3	Discontinued in Phase 1	Small molecular drug	[11]
AMELTOLIDE	DMALVX2	Discontinued in Phase 1	Small molecular drug	[12]
AWD-140-190	DMTG9EZ	Discontinued in Phase 1	NA	[13]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MB-03966	DM9KLQC	Investigative	NA	[14]
NAX-5055	DMO6T9C	Investigative	NA	[15]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215904.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7228).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4346).
• [4] SB-204269 SmithKline Beecham. IDrugs. 1998 Sep;1(5):595-8.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005914)
• [6] The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003609)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006296)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000082)
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5466).
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006181)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008003)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005495)
• [14] Engineered Adenosine-Releasing Cells for Epilepsy Therapy: Human Mesenchymal Stem Cells and Human Embryonic Stem Cells. Neurotherapeutics. 2009 April; 6(2): 278-283.
• [15] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.